Abstract
The confluence of Bupropion Hydrochloride and Naltrexone Hydrochloride within a composite pharmaceutical formulation has garnered the prestigious endorsement of the U.S. Food and Drug Administration (FDA) for its targeted application in addressing the pervasive issue of obesity. Naltrexone hydrochloride, a semi-synthetic opioid compound, exerts its therapeutic influence through competitive antagonism of the mu receptors, while Bupropion hydrochloride, a tricyclic antidepressant, operates by impeding the reuptake of dopamine, thus amplifying its activity in distinctive cerebral domains. Notably, Naltrexone's impact is modulated through the intricate manipulation of pro-opiomelanocortin neurons within the hypothalamus, underscoring the amalgamated efficacy of this unique tandem in the protracted management of obesity. This scholarly exposition focalizes on the meticulous delineation of high-performance liquid chromatography (HPLC)-based analytical methodologies, meticulously tailored for the concurrent quantification of naltrexone hydrochloride (NTX) and bupropion hydrochloride (BUP). This comprehensive review scrutinizes an array of analytical strategies, traversing from archetypal HPLC (high performance liquid chromatography) methodologies to the burgeoning realm of environmentally conscious chromatographic approaches. Each method undergoes scrupulous examination, elucidating the nuanced applications, from the constitution of the mobile phase and judicious column selection to the refinement of optimal flow rates. Moreover, the review orchestrates a comprehensive evaluation of the validation parameters intrinsic to these analytical approaches, fortifying the reliability and precision of their findings. This erudite exploration not only encapsulates the diversity of chromatographic techniques but also expounds on the methodological robustness that underpins the determination of these pharmacologically significant compounds. In doing so, it elevates the pursuit of scientific excellence in pharmaceutical analysis, contributing significantly to the ongoing discourse in this critical field. Article Highlights Explores wide range of HPLC based analytical procedures for simultaneous estimation of Naltrexone HCl and Bupropion HCl. Comprehensive evaluation of validation parameters to increase reliability and precision of methods. Simultaneous estimation of different API’s is advantageous in terms of saving cost, time, energy and resources Validates HPLC as an accurate, robust and technique of choice as an analytical tool.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Central Punjab, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Lahore, Pakistan (GRID:grid.444936.8) (ISNI:0000 0004 0608 9608)
2 National University of Sciences and Technology, Department of Biomedical Engineering and Sciences, School of Mechanical and Manufacturing Engineering, Islamabad, Pakistan (GRID:grid.412117.0) (ISNI:0000 0001 2234 2376)
3 Lahore Garrison University, Department of Chemistry, Lahore, Pakistan (GRID:grid.512552.4) (ISNI:0000 0004 5376 6253)





